<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168109">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01835899</url>
  </required_header>
  <id_info>
    <org_study_id>1305.2</org_study_id>
    <secondary_id>2012-005614-19</secondary_id>
    <nct_id>NCT01835899</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution in Healthy Male Volunteers q.d. or b.i.d.for 14 Days (a Randomised, Double-blind, Placebo-controlled Within Dose Groups Phase I Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate safety, tolerability, and pharmacokinetics of multiple rising oral doses of
      BI 1015550 in healthy male volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of patients with drug-related adverse events</measure>
    <time_frame>up to 24 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of BI 1015550 in plasma)</measure>
    <time_frame>up to 18 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt,1 (area under the concentration-time curve of BI 1015550 in plasma over a uniform dosing interval t after administration of the first dose)</measure>
    <time_frame>up to 18 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of BI 1015550 in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 18 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss (maximum measured concentration of BI 1015550 in plasma at steady state over a uniform dosing interval t)</measure>
    <time_frame>up to 18 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt,ss (area under the concentration-time curve of BI 1015550 in plasma at steady state over a uniform dosing interval t)</measure>
    <time_frame>up to 18 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo to BI 1015550</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1015550 low dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1015550 low dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1015550 medium dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1015550 medium dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>powder for oral solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to BI 1015550</description>
    <arm_group_label>Placebo to BI 1015550</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1015550</intervention_name>
    <description>medium dose 1 powder for oral solution</description>
    <arm_group_label>BI 1015550 medium dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1015550</intervention_name>
    <description>medium dose 2 powder for oral solution</description>
    <arm_group_label>BI 1015550 medium dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI1015550</intervention_name>
    <description>low dose 2 powder for oral solution</description>
    <arm_group_label>BI 1015550 low dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1015550</intervention_name>
    <description>low dose 1 powder for oral solution</description>
    <arm_group_label>BI 1015550 low dose 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. Healthy male subjects

        Exclusion criteria:

          1. Any relevant deviation from healthy conditions

          2. Subjects unable to understand or to comply with study requirements
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1305.2.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 9, 2013</lastchanged_date>
  <firstreceived_date>April 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
